CDTX Cidara Therapeutics Inc.

1.7
-0.01  -1%
Previous Close 1.71
Open 1.75
52 Week Low 1.46
52 Week High 4.34
Market Cap $82,092,652
Shares 48,289,795
Float 47,348,094
Enterprise Value $37,169,488
Volume 428,180
Av. Daily Volume 403,219
Stock charts supplied by TradingView

Upcoming Catalysts

Drug Stage Catalyst Date
Rezafungin (CD101) ReSTORE
Candidemia
Phase 3
Phase 3
Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 14-day FREE TRIAL.

Drug Pipeline

Drug Stage Notes
Rezafungin (CD101) - RADIANT
Vulvovaginal candidiasis (VVC)
Phase 2
Phase 2
Phase 2 data released February 21, 2017 - efficacy not evident, Development to be discontinued.
Rezafungin (CD101) ReSPECT
Prophylaxis
Phase 3
Phase 3
Phase 3 dosing of first patient announced May 20, 2020.
Rezafungin (CD101) STRIVE B
Candidemia
Phase 2
Phase 2
Phase 2 data released July 29, 2019 - noted all objectives met.

Latest News

  1. SAN DIEGO, July 27, 2021 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ:CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections, today announced that it will present clinical and pre-clinical data, including updated analyses from the Phase 2 STRIVE study and an in vitro evaluation of rezafungin activity against Candida and Aspergillus spp. isolates collected in Asia-Pacific countries, in two presentations at the International Society for Human and Animal Mycology (ISHAM) Asia Congress taking place virtually from August 6-8, 2021.

    Rezafungin is a novel once-weekly echinocandin currently being studied in Phase 3 trials for the…

    SAN DIEGO, July 27, 2021 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ:CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections, today announced that it will present clinical and pre-clinical data, including updated analyses from the Phase 2 STRIVE study and an in vitro evaluation of rezafungin activity against Candida and Aspergillus spp. isolates collected in Asia-Pacific countries, in two presentations at the International Society for Human and Animal Mycology (ISHAM) Asia Congress taking place virtually from August 6-8, 2021.

    Rezafungin is a novel once-weekly echinocandin currently being studied in Phase 3 trials for the treatment and prevention of serious fungal infections in critically ill patients. ISHAM Asia is a new conference aiming to increase opportunities for regional healthcare professionals and researchers and encourages their participation to interact with global leaders in the field of medical mycology.

    Presentation details are summarized below.

    Pre-Recorded Co-Sponsored Presentation followed by live Q&A:

    Title: Rezafungin: A novel, once-weekly echinocandin in phase 3 development for treatment and prevention of invasive fungal disease

    Presenter: Taylor Sandison, Chief Medical Officer, Cidara Therapeutics

    Session Date/Time: Friday, August 6, 2021 at 6:00 a.m. ET

    E-Poster Presentation:

    Title: Activity of rezafungin against clinical Candida and Aspergillus spp. isolates collected in Asia-Pacific (AP) countries (2014-2018)

    Presenter: Taylor Sandison, Chief Medical Officer, Cidara Therapeutics

    To register and view the full schedule, visit ISHAM Asia's website here. Copies of the presentations will be made available on the Publications section of Cidara's website.

    About Rezafungin

    Rezafungin is a novel once weekly echinocandin being developed for both the treatment and prevention of serious fungal infections, such as candidemia and invasive candidiasis. The structure and properties of rezafungin are specifically designed to improve upon a clinically validated mechanism intended to enhance its efficacy and safety potential for patients. Cidara is currently conducting a Phase 3 clinical trial with rezafungin for the first-line treatment of candidemia and/or invasive candidiasis (ReSTORE trial) and a second Phase 3 clinical trial of once-weekly rezafungin for the prevention of invasive fungal disease in patients undergoing allogeneic blood and marrow transplantation (ReSPECT trial).

    About Cidara Therapeutics

    Cidara is developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections. The Company's portfolio is comprised of its lead antifungal candidate, rezafungin, in addition to AVCs for the prevention and treatment of influenza and other viral diseases from Cidara's proprietary Cloudbreak® antiviral platform. Cidara is headquartered in San Diego, California. For more information, please visit www.cidara.com.

    INVESTOR CONTACT:

    Brian Ritchie

    LifeSci Advisors

    (212) 915-2578

    MEDIA CONTACT:

    Patrick Bursey

    LifeSci Communications

    (203) 430-9545



    Primary Logo

    View Full Article Hide Full Article
  2. Oral presentation shows clinical data demonstrating clearance of infection in initial days of treatment of candidemia following one dose of rezafungin compared to multiple daily doses of standard of care

    Three additional presentations to highlight areas of unmet medical needs to improve treatment of candidemia and invasive candidiasis

    SAN DIEGO, July 12, 2021 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ:CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections, today announced new analyses from multiple studies of rezafungin, Cidara's novel, once-weekly echinocandin, under investigation in Phase 3 development for the treatment…

    Oral presentation shows clinical data demonstrating clearance of infection in initial days of treatment of candidemia following one dose of rezafungin compared to multiple daily doses of standard of care

    Three additional presentations to highlight areas of unmet medical needs to improve treatment of candidemia and invasive candidiasis

    SAN DIEGO, July 12, 2021 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ:CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections, today announced new analyses from multiple studies of rezafungin, Cidara's novel, once-weekly echinocandin, under investigation in Phase 3 development for the treatment of candidemia and invasive candidiasis and prevention of invasive fungal infections, at the 31st European Congress of Clinical Microbiology and Infectious Diseases (ECCMID). Cidara's oral presentation discusses new efficacy data from a sub-analysis of the previously completed STRIVE Phase 2 trial. The scientific program includes three e-Posters on rezafungin and real world echinocandin use.

    "We are excited to present data, including new analyses from the STRIVE Phase 2 clinical trial, that reinforce rezafungin's potential as a therapy for the treatment of candidemia and invasive candidiasis," said Taylor Sandison, M.D., M.P.H., chief medical officer of Cidara. "We look forward to corroborating the results of our Phase 2 STRIVE program in our ongoing Phase 3 RESTORE trial in which we are testing whether the once-weekly, high front-loaded dosing of rezafungin can result in improved patient outcomes versus the daily dosing of standard of care. We are making significant progress in advancing the ReSTORE trial, with top-line data expected by the end of 2021."

    Alex Soriano, M.D., Ph.D., chief of infectious diseases service, University of Barcelona, added, "There are significant shortcomings related to the current standards of care for fungal infections, defined by high rates of morbidity and mortality, and limited efficacy and therapeutic options, that do not meet the needs of patients. Importantly, if we can clear infections faster, we may be able to improve patient outcomes. Therefore, these data demonstrating significant reduction in time to negative blood culture compared to caspofungin underscore the potential impact of rezafungin on the candidemia and invasive candidiasis treatment landscape, and I look forward to seeing the Phase 3 results later this year."

    Cidara's oral presentation, titled "Analysis of Efficacy from STRIVE Phase 2 Trial of Rezafungin Treatment of Candidemia and/or Invasive Candidiasis: Outcomes During Initial Days of Treatment," highlights a new sub-analysis from the STRIVE Phase 2 trial examining efficacy outcomes in the initial days of rezafungin treatment versus standard of care treatment with caspofungin. Key highlights include:

    • The percentage of patients with negative blood culture at 24 and 48 hours was higher in the rezafungin group than in the caspofungin group, as were rates of mycological cure and overall success at Day 5.
    • There was a statistically significant difference in the time to negative blood culture between rezafungin and caspofungin in patients with more aggressive infection, as defined by a positive blood culture between 12 hours before and 72 hours after enrollment.
    • In the STRIVE trial, in more than 200 patients enrolled, safety and tolerability findings were comparable between treatments, consistent with the established safety profile of the echinocandin class.
    • The ongoing Phase 3 ReSTORE trial (NCT03667690) will further contribute to the safety and efficacy database on rezafungin.

    STRIVE was an international, multicenter, double-blind, trial evaluating the safety, tolerability and efficacy of once-weekly intravenous dosing of rezafungin compared to once-daily dosing of caspofungin in patients with candidemia and/or invasive candidiasis.

    Key findings from Cidara's three e-Poster presentations are summarized below.

    Title: Analysis of Safety from STRIVE Phase 2 Trial of Rezafungin Treatment of Candidemia and/or Invasive Candidiasis: Assessment of Adverse Events and Laboratory Values

    • Additional safety endpoints, including liver function tests, were evaluated in patients with candidemia and/or invasive candidiasis treated with rezafungin once-weekly compared with caspofungin once daily.
    • Data demonstrate comparable safety of rezafungin to caspofungin in patients with candidemia and/or invasive candidiasis.

    Title: Development and validation of a modified EUCAST yeast broth microdilution MIC method for rezafungin to mitigate nonspecific binding through incorporation of Tween®20

    • Modified EUCAST yeast susceptibility testing method for rezafungin diminished variability without impacting the ability to differentiate fks mutant strains.
    • If successfully validated, rezafungin use would be enabled in this standardized broth-based antifungal susceptibility testing methodology.

    Title: A Multicenter Pharmacoepidemiologic Evaluation of Echinocandin Use

    • Analysis of real-world echinocandin use, across 20 U.S.-based hospitals, in 1,665 patients with positive Candida culture, showed that a significant proportion of echinocandin courses started during hospitalization and continued after discharge, with outpatient use more common for intra-abdominal related infections and candidemia.
    • Data demonstrated that the main reasons for continuing an echinocandin post hospital discharge were azole non-susceptible Candida and azole toxicity.

    Following the meeting, copies of the presentations will be made available on the Publications section of Cidara's website.

    About Rezafungin

    Rezafungin is a novel once-weekly echinocandin under investigation for both the treatment and prevention of serious fungal infections, such as candidemia and invasive candidiasis. The structure and properties of rezafungin are specifically designed to improve upon a clinically validated mechanism intended to enhance its efficacy and safety potential for patients. Cidara is currently conducting a Phase 3 clinical trial with rezafungin for the treatment of candidemia and/or invasive candidiasis (ReSTORE trial) and a second Phase 3 clinical trial of once-weekly rezafungin for the prevention of invasive fungal disease in patients undergoing allogeneic blood and marrow transplantation (ReSPECT trial).

    About Cidara Therapeutics

    Cidara is developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections. The Company's portfolio is comprised of its lead antifungal candidate, rezafungin, in addition to AVCs for the prevention and treatment of influenza and other viral diseases from Cidara's proprietary Cloudbreak® antiviral platform. Cidara is headquartered in San Diego, California. For more information, please visit www.cidara.com.

    Forward-Looking Statements

    This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "anticipates," "expect," "may," "plan" or "will". Forward-looking statements in this release include, but are not limited to, statements related to the potential for rezafungin to be a safe and effective treatment for candidemia and invasive candidiasis or to clear infections faster than the standard of care and improve patient outcomes, and whether the ReSTORE trial will be timely completed and top line data announced by the end of 2021. Such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, such as unanticipated delays in or negative results from Cidara's clinical trials, impacts of the COVID-19 pandemic on patient enrollment or other obstacles to the development of rezafungin. These and other risks are identified under the caption "Risk Factors" in Cidara's most recent Quarterly Report on Form 10-Q and other filings subsequently made with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management's assumptions and estimates as of such date. Cidara does not undertake any obligation to publicly update any forward-looking statements, whether as a result of the receipt of new information, the occurrence of future events or otherwise.

    INVESTOR CONTACT:

    Brian Ritchie

    LifeSci Advisors

    (212) 915-2578

    MEDIA CONTACT:

    Patrick Bursey

    LifeSci Communications

    (203) 430-9545

     



    Primary Logo

    View Full Article Hide Full Article
  3. SAN DIEGO, July 07, 2021 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections, today announced that the Compensation Committee of its Board of Directors granted non-qualified stock option awards and restricted stock units for an aggregate of 172,000 shares of its common stock to eight new employees, pursuant to the Cidara Therapeutics, Inc. 2020 Inducement Incentive Plan, with a grant date of June 30, 2021. Each of the stock options has an exercise price of $2.02 per share, which is equal to the closing price of Cidara's common stock on the grant date. The shares subject to the…

    SAN DIEGO, July 07, 2021 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections, today announced that the Compensation Committee of its Board of Directors granted non-qualified stock option awards and restricted stock units for an aggregate of 172,000 shares of its common stock to eight new employees, pursuant to the Cidara Therapeutics, Inc. 2020 Inducement Incentive Plan, with a grant date of June 30, 2021. Each of the stock options has an exercise price of $2.02 per share, which is equal to the closing price of Cidara's common stock on the grant date. The shares subject to the options will vest over four years, with 25% of the shares vesting on the one-year anniversary of the applicable vesting commencement date and the balance of the shares vesting in a series of 36 successive equal monthly installments thereafter. All RSUs vest in four equal annual installments, with 1/4 vesting on each of the first, second, third and fourth anniversaries of the Quarterly Vesting Date that occurs during the calendar quarter that includes the Date of Grant, subject to the participant's Continuous Service through each such vesting date. Quarterly Vesting Date means March 10, June 10, September 10 or December 10.The awards are subject to the award holders' continuous service through each vesting date and to the terms and conditions of the company's 2020 Inducement Incentive Plan and its standard forms of grant agreements thereunder.

    The foregoing equity awards were granted as inducements material to the employees entering into employment with Cidara, in accordance with Nasdaq Listing Rule 5635(c)(4). The Cidara Therapeutics, Inc. 2020 Inducement Incentive Plan is used exclusively for the grant of equity awards to individuals who were not previously employees of Cidara, or following a bona fide period of non-employment, as an inducement material to such individual's entering into employment with Cidara, pursuant to Nasdaq Listing Rule 5635(c)(4).

    About Cidara Therapeutics

    Cidara is developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections. The Company's portfolio is comprised of its lead antifungal candidate, rezafungin, in addition to antiviral conjugates (AVCs) for the prevention and treatment of influenza and other viral diseases from Cidara's proprietary Cloudbreak® antiviral platform. Cidara is headquartered in San Diego, California. For more information, please visit www.cidara.com.

    INVESTOR CONTACT:

    Brian Ritchie

    LifeSci Advisors

    (212) 915-2578

    MEDIA CONTACT:

    Karen O'Shea, Ph.D.

    LifeSci Communications

    (929) 469-3860



    Primary Logo

    View Full Article Hide Full Article
  4. SAN DIEGO, July 01, 2021 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ:CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections, today announced that James (Jamie) Levine has resigned from his position as chief financial officer (CFO), effective July 9, 2021, to pursue other opportunities. Mr. Levine will continue to serve as a consultant to the Company for at least six months and will provide transitional support to a successor CFO.

    "On behalf of the entire Cidara team and board of directors, I want to thank Jamie for his financial leadership, including his significant contributions to our collaborations with Mundipharma and…

    SAN DIEGO, July 01, 2021 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ:CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections, today announced that James (Jamie) Levine has resigned from his position as chief financial officer (CFO), effective July 9, 2021, to pursue other opportunities. Mr. Levine will continue to serve as a consultant to the Company for at least six months and will provide transitional support to a successor CFO.

    "On behalf of the entire Cidara team and board of directors, I want to thank Jamie for his financial leadership, including his significant contributions to our collaborations with Mundipharma and Janssen Pharmaceuticals," said Jeffrey Stein, Ph.D., president and chief executive officer of Cidara. "He has helped build an outstanding finance team and supported the strengthening of our balance sheet, which has enabled us to efficiently advance our rezafungin Phase 3 programs and expand our Cloudbreak immunotherapy antiviral platform. We wish Jamie the best in his future endeavors."

    Concurrent with Mr. Levine's resignation, Dr. Stein will assume the role of Cidara's principal financial officer, and Brady Johnson has been promoted to vice president, finance, and will assume the role of the Company's principal accounting officer.

    About Cidara Therapeutics

    Cidara is developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections. The Company's portfolio is comprised of its lead antifungal candidate, rezafungin, in addition to AVCs for the prevention and treatment of influenza and other viral diseases from Cidara's proprietary Cloudbreak® antiviral platform. Cidara is headquartered in San Diego, California. For more information, please visit www.cidara.com.

    INVESTOR CONTACT:

    Brian Ritchie

    LifeSci Advisors

    (212) 915-2578

    MEDIA CONTACT:

    Patrick Bursey

    LifeSci Communications

    (203) 430-9545



    Primary Logo

    View Full Article Hide Full Article
  5. SAN DIEGO, June 30, 2021 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ:CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections, today announced that it will present new analyses in four presentations, including an oral presentation on rezafungin, at the 31st European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), taking place virtually from July 9-12, 2021.

    Rezafungin is a novel once-weekly echinocandin currently being studied in Phase 3 trials for the treatment and prevention of serious fungal infections in critically ill and cancer patients.

    Abstracts selected for presentation are summarized below.

    SAN DIEGO, June 30, 2021 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ:CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections, today announced that it will present new analyses in four presentations, including an oral presentation on rezafungin, at the 31st European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), taking place virtually from July 9-12, 2021.

    Rezafungin is a novel once-weekly echinocandin currently being studied in Phase 3 trials for the treatment and prevention of serious fungal infections in critically ill and cancer patients.

    Abstracts selected for presentation are summarized below.

    Oral Presentation:

    Title: Analysis of Efficacy from STRIVE Phase 2 Trial of Rezafungin Treatment of Candidemia and/or Invasive Candidiasis: Outcomes During Initial Days of Treatment

    Presenter: Alex Soriano, M.D., Ph.D., University of Barcelona

    Session Date/Time: Saturday, July 10, 2021 at 7:55 p.m. ET

    On-Demand e-Poster Presentations:

    Title: Development and validation of a modified EUCAST yeast broth microdilution MIC method for rezafungin to mitigate nonspecific binding through incorporation of Tween®20

    Presenter: Jeffrey B Locke, Ph.D., Cidara

    • Selected for e-Poster review session, Antifungal drug resistance and beyond, on Sunday, July 11, 2021 from 9:30-10:00 a.m. ET

    Title: Analysis of Safety from STRIVE Phase 2 Trial of Rezafungin Treatment of Candidemia and/or Invasive Candidiasis: Assessment of Adverse Events and Laboratory Values

    Presenter: George R. Thompson III, M.D., University of California Davis Medical Center, Davis

    Title: A Multicenter Pharmacoepidemiologic Evaluation of Echinocandin Use

    Presenter: Jinhee Jo, Pharm.D., University of Houston

    To register and view the full schedule, visit ECCMID 2021's website here. Copies of the presentations will be made available on the Publications section of Cidara's website.

    About Rezafungin

    Rezafungin is a novel once weekly echinocandin being developed for both the treatment and prevention of serious fungal infections, such as candidemia and invasive candidiasis. The structure and properties of rezafungin are specifically designed to improve upon a clinically validated mechanism intended to enhance its efficacy and safety potential for patients. Cidara is currently conducting a Phase 3 clinical trial with rezafungin for the first-line treatment of candidemia and/or invasive candidiasis (ReSTORE trial) and a second Phase 3 clinical trial of once-weekly rezafungin for the prevention of invasive fungal disease in patients undergoing allogeneic blood and marrow transplantation (ReSPECT trial).

    About Cidara Therapeutics

    Cidara is developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections. The Company's portfolio is comprised of its lead antifungal candidate, rezafungin, in addition to AVCs for the prevention and treatment of influenza and other viral diseases from Cidara's proprietary Cloudbreak® antiviral platform. Cidara is headquartered in San Diego, California. For more information, please visit www.cidara.com.

    INVESTOR CONTACT:

    Brian Ritchie

    LifeSci Advisors

    (212) 915-2578

    MEDIA CONTACT:

    Patrick Bursey

    LifeSci Communications

    (203) 430-9545



    Primary Logo

    View Full Article Hide Full Article
View All Cidara Therapeutics Inc. News